secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edesa Biotech, Inc. (EDSA)
CIK:        0001540159
Form:       8-K
Filed at:   2026-06-05T13:25:18+00:00
Accession:  0001171843-26-003931
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Edesa Biotech: paridiprubart shows 32% relative mortality reduction in AKI/ARDS patients
--------------------------------------------------------------------------------

- Exploratory Phase 3 data: paridiprubart + SOC reduced 28-day mortality to 33% vs 49% placebo (p<0.005).
- MAKE30 composite endpoint incidence reduced to 41% from 53% (23% relative reduction, p<0.005).
- AKI cohort of 101 severely ill patients (90% moderate-to-severe ARDS, ~50% on ventilation/ECMO).
- Paridiprubart well tolerated; no significant differences in adverse events vs placebo.
- Data presented at ERA Congress 2026; results exploratory and require confirmatory studies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1540159/000117184326003931/0001171843-26-003931-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1540159/000117184326003931/f8k_060226.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-003931

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer